Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB
SETTING: Data were collected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon.OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin (LVX) based STR on bact...
Gespeichert in:
| Veröffentlicht in: | The international journal of tuberculosis and lung disease 2019-09, Vol.23 (9), p.965-971 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 971 |
|---|---|
| container_issue | 9 |
| container_start_page | 965 |
| container_title | The international journal of tuberculosis and lung disease |
| container_volume | 23 |
| creator | Van Deun, A. Decroo, T. Kuaban, C. Noeske, J. Piubello, A. Aung, K. J. M. Rieder, H. L. |
| description | SETTING: Data were collected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon.OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin
(LVX) based STR on bacteriological effectiveness.DESIGN: Retrospective study of prospectively collected data.RESULTS: Among 1530 patients, bacteriological effectiveness was 96.7% overall. Stratified by treatment with a GFX-, LVX- or MFX-based regimen effectiveness was
respectively 97.5%, 95.5% and 94.7%. Compared to those on a GFX-based regimen, the estimated summary odds ratio of having an adverse outcome was more than double (OR 2.05, 95% CI 1.09-3.90) in patients treated with either an LVX-based or MFX-based regimen. After adjusting for initial
resistance, patients treated with an LVX-based regimen and MFX-based regimen had respectively a 4.5- and 8.4-fold times larger odds of an adverse bacteriological outcome. None among 859 patients at risk treated with a GFX-based compared to at least 4 of 228 among those on an MFX-based regimen
acquired fluoroquinolone resistance.CONCLUSION: GFX-based regimens had superior bacteriological effectiveness than MFX-based or LVX-based regimens. As GFX is currently unavailable in most MDR-TB programs, its reintroduction should be prioritised. |
| doi_str_mv | 10.5588/ijtld.19.0053 |
| format | Article |
| fullrecord | <record><control><sourceid>pubtec_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2306214655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>iuatld/ijtld/2019/00000023/00000009/art00002</ingid><sourcerecordid>iuatld/ijtld/2019/00000023/00000009/art00002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-17f6700e94b082e5f2d5b6675d052fb710d6b66b2a58e92513415bc2d89b56913</originalsourceid><addsrcrecordid>eNp1ksFvFCEUh4nR2Lp69Gom8eJlVh7MY4aj1raaNNFDPRNmYFY2M8MKTNP618t0ttWYyIUHfPkg7wchr4FuEZvmvdunwWxBbilF_oScQgNY1pLRp7mmrC55DfKEvIhxTykDgPo5OeEgAAVlpyRc6uT6wd_qzk2Fi0WcDzY4H4rki8He-MczPZli9Ld_wVMRf_iQbGaD1Wm0UyqC3blcxKLPinEekjNh3pXBRheTzsD1x5fkWa-HaF8d5w35fnF-ffa5vPp6-eXsw1XZVYiphLoXNaVWVi1tmMWeGWyFqNFQZH1bAzUir1umsbGSIfAKsO2YaWSLQgLfkHer9xD8z9nGpEYXOzsMerJ-jopxKhhUAjGjb_9B934OU37dQlUUuGhYpsqV6oKPMdheHYIbdbhTQNUShroPQ4FUSxiZf3O0zu1ozSP90P0MfFoBN-1y8_SfW92sF9PqY_TeuAzGjwWVSoe0bm3It_9pugfT8hWWn6BuGJ9kVjLIXUUFmE3G9jpHpZIOavdLRcZ_A41yt4s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2304013682</pqid></control><display><type>article</type><title>Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Van Deun, A. ; Decroo, T. ; Kuaban, C. ; Noeske, J. ; Piubello, A. ; Aung, K. J. M. ; Rieder, H. L.</creator><creatorcontrib>Van Deun, A. ; Decroo, T. ; Kuaban, C. ; Noeske, J. ; Piubello, A. ; Aung, K. J. M. ; Rieder, H. L.</creatorcontrib><description>SETTING: Data were collected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon.OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin
(LVX) based STR on bacteriological effectiveness.DESIGN: Retrospective study of prospectively collected data.RESULTS: Among 1530 patients, bacteriological effectiveness was 96.7% overall. Stratified by treatment with a GFX-, LVX- or MFX-based regimen effectiveness was
respectively 97.5%, 95.5% and 94.7%. Compared to those on a GFX-based regimen, the estimated summary odds ratio of having an adverse outcome was more than double (OR 2.05, 95% CI 1.09-3.90) in patients treated with either an LVX-based or MFX-based regimen. After adjusting for initial
resistance, patients treated with an LVX-based regimen and MFX-based regimen had respectively a 4.5- and 8.4-fold times larger odds of an adverse bacteriological outcome. None among 859 patients at risk treated with a GFX-based compared to at least 4 of 228 among those on an MFX-based regimen
acquired fluoroquinolone resistance.CONCLUSION: GFX-based regimens had superior bacteriological effectiveness than MFX-based or LVX-based regimens. As GFX is currently unavailable in most MDR-TB programs, its reintroduction should be prioritised.</description><identifier>ISSN: 1027-3719</identifier><identifier>EISSN: 1815-7920</identifier><identifier>DOI: 10.5588/ijtld.19.0053</identifier><identifier>PMID: 31615602</identifier><language>eng</language><publisher>France: International Union Against Tuberculosis and Lung Disease</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibiotics ; Antitubercular Agents - administration & dosage ; Bacteriological Effectiveness ; Bangladesh ; Cameroon ; Child ; Core Drug ; Drug Administration Schedule ; Drug resistance ; Female ; Gatifloxacin ; Gatifloxacin - administration & dosage ; Humans ; Levofloxacin ; Levofloxacin - administration & dosage ; Male ; Middle Aged ; Moxifloxacin ; Moxifloxacin - administration & dosage ; Multidrug resistance ; Multidrug resistant organisms ; Niger ; Reintroduction ; Retrospective Studies ; Short tandem repeats ; Treatment Outcome ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy ; Tuberculosis, Multidrug-Resistant - microbiology ; Young Adult</subject><ispartof>The international journal of tuberculosis and lung disease, 2019-09, Vol.23 (9), p.965-971</ispartof><rights>Copyright International Union against Tuberculosis and Lung Disease (IUATLD) Sep 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-17f6700e94b082e5f2d5b6675d052fb710d6b66b2a58e92513415bc2d89b56913</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31615602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Deun, A.</creatorcontrib><creatorcontrib>Decroo, T.</creatorcontrib><creatorcontrib>Kuaban, C.</creatorcontrib><creatorcontrib>Noeske, J.</creatorcontrib><creatorcontrib>Piubello, A.</creatorcontrib><creatorcontrib>Aung, K. J. M.</creatorcontrib><creatorcontrib>Rieder, H. L.</creatorcontrib><title>Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB</title><title>The international journal of tuberculosis and lung disease</title><addtitle>Int J Tuberc Lung Dis</addtitle><description>SETTING: Data were collected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon.OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin
(LVX) based STR on bacteriological effectiveness.DESIGN: Retrospective study of prospectively collected data.RESULTS: Among 1530 patients, bacteriological effectiveness was 96.7% overall. Stratified by treatment with a GFX-, LVX- or MFX-based regimen effectiveness was
respectively 97.5%, 95.5% and 94.7%. Compared to those on a GFX-based regimen, the estimated summary odds ratio of having an adverse outcome was more than double (OR 2.05, 95% CI 1.09-3.90) in patients treated with either an LVX-based or MFX-based regimen. After adjusting for initial
resistance, patients treated with an LVX-based regimen and MFX-based regimen had respectively a 4.5- and 8.4-fold times larger odds of an adverse bacteriological outcome. None among 859 patients at risk treated with a GFX-based compared to at least 4 of 228 among those on an MFX-based regimen
acquired fluoroquinolone resistance.CONCLUSION: GFX-based regimens had superior bacteriological effectiveness than MFX-based or LVX-based regimens. As GFX is currently unavailable in most MDR-TB programs, its reintroduction should be prioritised.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibiotics</subject><subject>Antitubercular Agents - administration & dosage</subject><subject>Bacteriological Effectiveness</subject><subject>Bangladesh</subject><subject>Cameroon</subject><subject>Child</subject><subject>Core Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug resistance</subject><subject>Female</subject><subject>Gatifloxacin</subject><subject>Gatifloxacin - administration & dosage</subject><subject>Humans</subject><subject>Levofloxacin</subject><subject>Levofloxacin - administration & dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Moxifloxacin</subject><subject>Moxifloxacin - administration & dosage</subject><subject>Multidrug resistance</subject><subject>Multidrug resistant organisms</subject><subject>Niger</subject><subject>Reintroduction</subject><subject>Retrospective Studies</subject><subject>Short tandem repeats</subject><subject>Treatment Outcome</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - microbiology</subject><subject>Young Adult</subject><issn>1027-3719</issn><issn>1815-7920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ksFvFCEUh4nR2Lp69Gom8eJlVh7MY4aj1raaNNFDPRNmYFY2M8MKTNP618t0ttWYyIUHfPkg7wchr4FuEZvmvdunwWxBbilF_oScQgNY1pLRp7mmrC55DfKEvIhxTykDgPo5OeEgAAVlpyRc6uT6wd_qzk2Fi0WcDzY4H4rki8He-MczPZli9Ld_wVMRf_iQbGaD1Wm0UyqC3blcxKLPinEekjNh3pXBRheTzsD1x5fkWa-HaF8d5w35fnF-ffa5vPp6-eXsw1XZVYiphLoXNaVWVi1tmMWeGWyFqNFQZH1bAzUir1umsbGSIfAKsO2YaWSLQgLfkHer9xD8z9nGpEYXOzsMerJ-jopxKhhUAjGjb_9B934OU37dQlUUuGhYpsqV6oKPMdheHYIbdbhTQNUShroPQ4FUSxiZf3O0zu1ozSP90P0MfFoBN-1y8_SfW92sF9PqY_TeuAzGjwWVSoe0bm3It_9pugfT8hWWn6BuGJ9kVjLIXUUFmE3G9jpHpZIOavdLRcZ_A41yt4s</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Van Deun, A.</creator><creator>Decroo, T.</creator><creator>Kuaban, C.</creator><creator>Noeske, J.</creator><creator>Piubello, A.</creator><creator>Aung, K. J. M.</creator><creator>Rieder, H. L.</creator><general>International Union Against Tuberculosis and Lung Disease</general><general>International Union against Tuberculosis and Lung Disease (IUATLD)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20190901</creationdate><title>Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB</title><author>Van Deun, A. ; Decroo, T. ; Kuaban, C. ; Noeske, J. ; Piubello, A. ; Aung, K. J. M. ; Rieder, H. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-17f6700e94b082e5f2d5b6675d052fb710d6b66b2a58e92513415bc2d89b56913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibiotics</topic><topic>Antitubercular Agents - administration & dosage</topic><topic>Bacteriological Effectiveness</topic><topic>Bangladesh</topic><topic>Cameroon</topic><topic>Child</topic><topic>Core Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug resistance</topic><topic>Female</topic><topic>Gatifloxacin</topic><topic>Gatifloxacin - administration & dosage</topic><topic>Humans</topic><topic>Levofloxacin</topic><topic>Levofloxacin - administration & dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Moxifloxacin</topic><topic>Moxifloxacin - administration & dosage</topic><topic>Multidrug resistance</topic><topic>Multidrug resistant organisms</topic><topic>Niger</topic><topic>Reintroduction</topic><topic>Retrospective Studies</topic><topic>Short tandem repeats</topic><topic>Treatment Outcome</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - microbiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Deun, A.</creatorcontrib><creatorcontrib>Decroo, T.</creatorcontrib><creatorcontrib>Kuaban, C.</creatorcontrib><creatorcontrib>Noeske, J.</creatorcontrib><creatorcontrib>Piubello, A.</creatorcontrib><creatorcontrib>Aung, K. J. M.</creatorcontrib><creatorcontrib>Rieder, H. L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The international journal of tuberculosis and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Deun, A.</au><au>Decroo, T.</au><au>Kuaban, C.</au><au>Noeske, J.</au><au>Piubello, A.</au><au>Aung, K. J. M.</au><au>Rieder, H. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB</atitle><jtitle>The international journal of tuberculosis and lung disease</jtitle><addtitle>Int J Tuberc Lung Dis</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>23</volume><issue>9</issue><spage>965</spage><epage>971</epage><pages>965-971</pages><issn>1027-3719</issn><eissn>1815-7920</eissn><abstract>SETTING: Data were collected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon.OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin
(LVX) based STR on bacteriological effectiveness.DESIGN: Retrospective study of prospectively collected data.RESULTS: Among 1530 patients, bacteriological effectiveness was 96.7% overall. Stratified by treatment with a GFX-, LVX- or MFX-based regimen effectiveness was
respectively 97.5%, 95.5% and 94.7%. Compared to those on a GFX-based regimen, the estimated summary odds ratio of having an adverse outcome was more than double (OR 2.05, 95% CI 1.09-3.90) in patients treated with either an LVX-based or MFX-based regimen. After adjusting for initial
resistance, patients treated with an LVX-based regimen and MFX-based regimen had respectively a 4.5- and 8.4-fold times larger odds of an adverse bacteriological outcome. None among 859 patients at risk treated with a GFX-based compared to at least 4 of 228 among those on an MFX-based regimen
acquired fluoroquinolone resistance.CONCLUSION: GFX-based regimens had superior bacteriological effectiveness than MFX-based or LVX-based regimens. As GFX is currently unavailable in most MDR-TB programs, its reintroduction should be prioritised.</abstract><cop>France</cop><pub>International Union Against Tuberculosis and Lung Disease</pub><pmid>31615602</pmid><doi>10.5588/ijtld.19.0053</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1027-3719 |
| ispartof | The international journal of tuberculosis and lung disease, 2019-09, Vol.23 (9), p.965-971 |
| issn | 1027-3719 1815-7920 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2306214655 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Antibiotics Antitubercular Agents - administration & dosage Bacteriological Effectiveness Bangladesh Cameroon Child Core Drug Drug Administration Schedule Drug resistance Female Gatifloxacin Gatifloxacin - administration & dosage Humans Levofloxacin Levofloxacin - administration & dosage Male Middle Aged Moxifloxacin Moxifloxacin - administration & dosage Multidrug resistance Multidrug resistant organisms Niger Reintroduction Retrospective Studies Short tandem repeats Treatment Outcome Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - microbiology Young Adult |
| title | Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T15%3A38%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubtec_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gatifloxacin%20is%20superior%20to%20levofloxacin%20and%20moxifloxacin%20in%20shorter%20treatment%20regimens%20for%20multidrug-resistant%20TB&rft.jtitle=The%20international%20journal%20of%20tuberculosis%20and%20lung%20disease&rft.au=Van%20Deun,%20A.&rft.date=2019-09-01&rft.volume=23&rft.issue=9&rft.spage=965&rft.epage=971&rft.pages=965-971&rft.issn=1027-3719&rft.eissn=1815-7920&rft_id=info:doi/10.5588/ijtld.19.0053&rft_dat=%3Cpubtec_proqu%3Eiuatld/ijtld/2019/00000023/00000009/art00002%3C/pubtec_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2304013682&rft_id=info:pmid/31615602&rft_ingid=iuatld/ijtld/2019/00000023/00000009/art00002&rfr_iscdi=true |